{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-117981","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.868607+00:00","generated_at":"2026-05-16T15:01:41.555218+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Capricor provides HOPE-3 trial update via slide presentation, no new data disclosed","bullets":["Filed Item 7.01 with slide presentation dated Dec 3, 2025 on HOPE-3 Phase 3 top-line results.","Slide presentation contains no specific efficacy or safety numbers in the attached exhibit.","Company held conference call; full slides available on investor website.","No materially new financial or clinical information beyond prior top-line announcement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-117981","json":"https://secwatch.observer/filing/0001104659-25-117981.json","markdown":"https://secwatch.observer/filing/0001104659-25-117981.md","text":"https://secwatch.observer/filing/0001104659-25-117981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925117981/0001104659-25-117981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000110465925117981/capr-20251203x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:01:41.555218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}